Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director · Interim President & CEO | February 14, 2025 | February 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date February 14, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,658,003 |
Reported balance
After 2025-02-14 transaction · row 1
1 source rowRow 1 · 2025-02-14 · Grant · Acquired 177,000 · Balance 1,658,003 F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.29 · Expires 2035-02-14 | Direct | 718,800 |
Reported balance
After 2025-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-14 · Grant · Acquired 718,800 · Balance 718,800 F2: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 19, 2025 23:25 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 718,800 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001447028-25-000051 · wk-form4_1740007534.xml · derivative · entry 2 McElhaugh Michael J. · CIK 0001635326 · Director · Interim President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 718,800 Underlying: Common Shares · 718,800 shares Expires 2035-02-14 F2 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F3 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 23:25 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Shares | 177,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001447028-25-000051 · wk-form4_1740007534.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Director · Interim President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,658,003 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:02 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | SaleCommon Shares | 23,790 | $3.28 | $78,102.57 |
DisclosureSEC source: 0001447028-25-000038 · wk-form4_1738789341.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Director · Interim President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,481,003 F1 · kind: Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 3, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 00:54 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | SaleCommon Shares | 10,164 | $2.31 | $23,504.25 |
DisclosureSEC source: 0001447028-24-000025 · wk-form4_1707180834.xml · nonDerivative · entry 2 McElhaugh Michael J. · CIK 0001635326 · Director · Interim President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,504,793 F2 · kind: Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 3, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:54 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 495,100 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001447028-24-000025 · wk-form4_1707180834.xml · derivative · entry 3 McElhaugh Michael J. · CIK 0001635326 · Director · Interim President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 495,100 Underlying: Common Shares · 495,100 shares Expires 2034-02-01 F3 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F4 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:54 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Shares | 123,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001447028-24-000025 · wk-form4_1707180834.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Director · Interim President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,514,957 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:12 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 334,700 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001447028-23-000011 · wf-form4_167545871089009.xml · derivative · entry 2 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,700 Underlying: Common Shares · 334,700 shares Expires 2033-02-01 F2 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:12 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Shares | 83,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001447028-23-000011 · wf-form4_167545871089009.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,391,157 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document |
| January 20, 2022 Filed Jan 20, 2022 22:53 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 325,850 | $2.81 Strike: $2.81 | $915,638.50 |
DisclosureSEC source: 0001447028-22-000007 · wf-form4_164271921610822.xml · derivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,850 Underlying: Common Shares · 325,850 shares Expires 2032-01-20 F1 · derivative.exercise_date: These stock options will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 13, 2021 Filed Feb 17, 2021 21:55 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 249,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001447028-21-000006 · wf-form4_161359884797554.xml · derivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,000 Underlying: Common Stock · 249,000 shares Expires 2031-02-13 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 22:06 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | SaleCommon Stock | 20,000 | $5.00 | $100,000.00 |
DisclosureSEC source: 0001447028-21-000002 · wf-form4_161299476323256.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,307,457 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:33 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | SaleCommon Stock | 10,000 | $5.00 | $50,032.00 |
DisclosureSEC source: 0001447028-20-000152 · wf-form4_160815442050068.xml · nonDerivative · entry 2 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,327,457 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:33 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | SaleCommon Stock | 30,000 | $5.00 | $150,000.00 |
DisclosureSEC source: 0001447028-20-000152 · wf-form4_160815442050068.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,337,457 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2020. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:27 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | SaleCommon Stock | 20,000 | $5.01 | $100,200.00 |
DisclosureSEC source: 0001447028-20-000080 · wf-form4_159588525290974.xml · nonDerivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367,457 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2020. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 13:02 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001447028-20-000026 · wf-form4_158211733691572.xml · derivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The stock option will vest and become exercisable 1/48th each month over the four year period. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:07 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 104,500 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000436 · edgar.xml · derivative · entry 1 McElhaugh Michael J. · CIK 0001635326 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,500 Underlying: Common Shares · 104,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.